CS23546 is a small molecule PD-L1 inhibitor independently developed by Chipscreen Biosciences. By binding to PD-L1 and inducing its endocytosis, it cancels immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway.

In preclinical studies, CS23546 showed good oral absorption and metabolic characteristics of local tumor tissue concentration. A single drug had significant antitumor efficacy against different tumor transplantation models, and combined chemotherapy or the Company's varieties such as chidamide and chiauranib could produce significant synergistic antitumor activity. The CS23546 product process is stable and the quality is controllable. As a next-generation oral small molecule immune checkpoint inhibitor, it is expected to bring differentiated advantages in the clinical treatment of different malignant tumors. At the same time, it has application potential for other immune-related diseases mediated by PD-L1 signals.

In June 2023, CS23546 has been approved for clinical trials in advanced malignant tumors in China, and the phase I dose escalation of CS23546 is currently progressing as planned.